Clinical Trial Update: Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents [Phase 4]

View source ↗

Summary

Phase 4 trial updating the appropriate duration of antiplatelet and thrombotic therapy after 12 months in patients with atrial fibrillation treated with drug-el…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: Yonsei University | Conditions: Atrial Fibrillation | Phase 4 | Status: ACTIVE_NOT_RECRUITING